Boehringer and Lilly present positive cardiovascular data for Jardiance

5 November 2018
boehringer_big

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released positive initial results from the real-world EMPRISE study examining cardiovascular outcomes related to Jardiance (empagliflozin).

The study shows treatment with Jardiance was associated with a 44% relative risk reduction in hospitalization for heart failure (HHF), compared with dipeptidyl peptidase-4 (DPP-4) inhibitors.

The study looked at around 35,000 people with type 2 diabetes, and support findings from the EMPA-REG OUTCOME trial, which showed a 35% relative risk reduction in HHF compared with placebo, when added to standard of care.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical